Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.

Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, Perri MG, Pi-Sunyer FX, Rock CL, Erickson JS, Maier HN, Kim DD, Dunayevich E.

Obesity (Silver Spring). 2011 Jan;19(1):110-20. doi: 10.1038/oby.2010.147. Epub 2010 Jun 17.

PMID:
20559296
[PubMed - indexed for MEDLINE]
2.

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).

Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, Kim D, Dunayevich E; COR-II Study Group.

Obesity (Silver Spring). 2013 May;21(5):935-43. doi: 10.1002/oby.20309.

PMID:
23408728
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.

Greenway FL, Dunayevich E, Tollefson G, Erickson J, Guttadauria M, Fujioka K, Cowley MA; NB-201 Study Group.

J Clin Endocrinol Metab. 2009 Dec;94(12):4898-906. doi: 10.1210/jc.2009-1350. Epub 2009 Oct 21.

PMID:
19846734
[PubMed - indexed for MEDLINE]
4.

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.

Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER, Leadbetter RA, Richard N, Haight B, Jamerson BD, Buaron KS, Metz A.

Obes Res. 2002 Oct;10(10):1049-56.

PMID:
12376586
[PubMed - indexed for MEDLINE]
5.

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM.

Obes Res. 2002 Jul;10(7):633-41.

PMID:
12105285
[PubMed - indexed for MEDLINE]
6.

Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.

Padwal R.

Curr Opin Investig Drugs. 2009 Oct;10(10):1117-25. Review.

PMID:
19777400
[PubMed - indexed for MEDLINE]
7.

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E; COR-I Study Group.

Lancet. 2010 Aug 21;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29. Erratum in: Lancet. 2010 Oct 23;376(9750):1392. Lancet. 2010 Aug 21;376(9741):594.

PMID:
20673995
[PubMed - indexed for MEDLINE]
8.

Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?

Katsiki N, Hatzitolios AI, Mikhailidis DP.

Ann Med. 2011 Jun;43(4):249-58. doi: 10.3109/07853890.2010.541490. Epub 2011 Jan 24. Review.

PMID:
21254901
[PubMed - indexed for MEDLINE]
9.

Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis.

Weiner E, Ball MP, Buchholz AS, Gold JM, Evins AE, McMahon RP, Buchanan RW.

J Clin Psychiatry. 2012 Jan;73(1):95-102. doi: 10.4088/JCP.10m06143gre. Epub 2011 Apr 5.

PMID:
21535998
[PubMed - indexed for MEDLINE]
10.

Naltrexone/bupropion: an investigational combination for weight loss and maintenance.

Makowski CT, Gwinn KM, Hurren KM.

Obes Facts. 2011;4(6):489-94. doi: 10.1159/000335352. Epub 2011 Dec 15. Review.

PMID:
22249001
[PubMed - indexed for MEDLINE]
11.

Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo.

Jamerson BD, Nides M, Jorenby DE, Donahue R, Garrett P, Johnston JA, Fiore MC, Rennard SI, Leischow SJ.

Clin Ther. 2001 May;23(5):744-52.

PMID:
11394732
[PubMed - indexed for MEDLINE]
12.

Combination therapy with naltrexone and bupropion for obesity.

Billes SK, Greenway FL.

Expert Opin Pharmacother. 2011 Aug;12(11):1813-26. doi: 10.1517/14656566.2011.591382. Epub 2011 Jun 21. Review.

PMID:
21689063
[PubMed - indexed for MEDLINE]
13.

Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity.

Plodkowski RA, Nguyen Q, Sundaram U, Nguyen L, Chau DL, St Jeor S.

Expert Opin Pharmacother. 2009 Apr;10(6):1069-81. doi: 10.1517/14656560902775750 . Review.

PMID:
19364254
[PubMed - indexed for MEDLINE]
14.

A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.

Reimherr FW, Cunningham LA, Batey SR, Johnston JA, Ascher JA.

Clin Ther. 1998 May-Jun;20(3):505-16.

PMID:
9663366
[PubMed - indexed for MEDLINE]
15.

Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial.

Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, Sachs DP, Wolter TD, Buist AS, Johnston JA, White JD.

Ann Intern Med. 2001 Sep 18;135(6):423-33.

PMID:
11560455
[PubMed - indexed for MEDLINE]
16.

Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study.

Dannon PN, Lowengrub K, Musin E, Gonopolski Y, Kotler M.

J Clin Psychopharmacol. 2005 Dec;25(6):593-6.

PMID:
16282845
[PubMed - indexed for MEDLINE]
17.

Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study.

Gadde KM, Yonish GM, Foust MS, Wagner HR.

J Clin Psychiatry. 2007 Aug;68(8):1226-9.

PMID:
17854247
[PubMed - indexed for MEDLINE]
18.

Safety profile of sustained-release bupropion in depression: results of three clinical trials.

Settle EC, Stahl SM, Batey SR, Johnston JA, Ascher JA.

Clin Ther. 1999 Mar;21(3):454-63.

PMID:
10321415
[PubMed - indexed for MEDLINE]
19.

Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL.

Lancet. 2011 Apr 30;377(9776):1506-13. doi: 10.1016/S0140-6736(11)60358-9.

PMID:
21529928
[PubMed - indexed for MEDLINE]
20.

Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women.

Gadde KM, Parker CB, Maner LG, Wagner HR 2nd, Logue EJ, Drezner MK, Krishnan KR.

Obes Res. 2001 Sep;9(9):544-51.

PMID:
11557835
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk